Syros Pharmaceuticals Inc. (SYRS): Check on its recent ratings


Syros Pharmaceuticals Inc. (NASDAQ:SYRS) changes shares on Monday trading session, with a change of 2.72% or $0.27 shares. The trading starts at $9.88 and closed at $9.93 throughout the day. The trading session low price was $9.65 and day high was $10.43 on Monday, June 22. After the session, the Healthcare sector daily volume shifted to 0.39 million while its average volume is 345.21K. In other hand, the SYRS market cap reached to $460.94M. While, its current target price is $10.20 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 10.63% and up 7.37% for month. Its quarterly performance was 77.70% above, while its half year performance is up 64.12%. SYRS yearly performance stood at positive 49.34% and rise 47.61% for year-to-date. Current recommendation for Syros Pharmaceuticals Inc. is 2.10.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. SYRS EPS (TTM) for 12-month is -1.79. EPS for this year is 1.70%, while for the next year its value is -1.64. Its EPS Q/Q reached 19.60%. It has an EPS of -22.20% down for past five years.

Let’s take a look on the analyst recommendations on SYRS for the current month and previous month. For the current month, 6 of 8 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $8.00-$17.00. Average target price for SYRS was reached at $12.86.

FMR, LLC, ARK Investment Management, LLC and Nikko Asset Management Americas, Inc. are the top three holders in Syros Pharmaceuticals Inc. (SYRS) stock. On Mar 30, 2020, FMR, LLC has 6.28 million shares which valued 37.23 million. On Mar 30, 2020, ARK Investment Management, LLC owned 5.9 million shares which valued at 34.98 million. On Mar 30, 2020, Nikko Asset Management Americas, Inc. has a total of 4.93 million shares which valued at 29.21 million. In the end, Nikko Asset Management Americas, Inc. have 10.78% shares outstanding of Syros Pharmaceuticals Inc. (SYRS) on Mar 30, 2020. The insider ownership moved to 2.00% and institutional holding shifted to 88.80%.

The company posted an EPS (TTM) of -1.79. According to the most recent quarter report on (Jun 2020), 8 analysts estimated an average EPS of -0.4, while -0.47 EPS posted a year ago period. Analyst Estimated EPS for SYRS published in the report was -0.44–0.32 during the same period. Comparing with last year, the average estimated EPS was -0.47 which is lower than -0.39 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for SYRS rise 36.48% for period of 200 days. SMA for 50 days was 12.55% which is showing green signal, while SMA-20 was 8.10%. The moving average value for Syros Pharmaceuticals Inc. (SYRS) is 7.50 and 9.39 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in SYRS stock. On Jun 15, Young Richard A, Director, sold 5,990 trading shares at the cost of $8.75, which valued at 52413.0. On May 15, Young Richard A, Director, sold 5,990 shares at the cost of $9.22, with total shares of 365,151. On May 13, Alles Mark J, Director, bought 10,000 shares at the cost of 8.86. After this transaction, Alles Mark J total shares reached to 10,000 which valued at 88590.0.